✦ LIBER ✦

Metabolic syndrome and prostate cancer

✍ Scribed by L. Michael Glode

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 50 KB
Volume: 112
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.23511

No coin nor oath required. For personal study only.

✦ Synopsis

The metabolic syndrome (MetS) was first proposed as a clinical entity in 1988 and has been popularized by numerous health organizations as a way of identifying patients at increased risk for coronary heart disease or type II diabetes. The numerous definitions for MetS has made it somewhat difficult for practicing physicians to adopt a standard and then apply it to behavioral modification and/or pharmacologic therapy for their patients. In this issue of Cancer, Smith et al. performed a prospective analysis of some components of MetS in 26 men with locally advanced or recurrent prostate cancer who were treated with 1 year of leuprolide in addition to 1 month of bicalutamide at the time of the initiation of gonadotropin‒releasing hormone agonist therapy. Some differences between classic MetS and the androgen deprivation syndrome were demonstrated.

📜 SIMILAR VOLUMES

Features of the metabolic syndrome and p

Features of the metabolic syndrome and prostate cancer in African-American men

✍ Jennifer L. Beebe-Dimmer; Rodney L. Dunn; Aruna V. Sarma; James E. Montie; Kathl 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 2 views

Metabolic changes during gonadotropin-re

Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer : Differences from the classic metabolic syndrome

✍ Matthew R. Smith; Hang Lee; Francis McGovern; Mary Anne Fallon; Melissa Goode; A 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB

## Abstract ## BACKGROUND. In men with prostate cancer, gonadotropin‐releasing hormone (GnRH) agonists increase fat mass, decrease insulin sensitivity, and increase triglycerides, features that are shared with metabolic syndrome. To the authors' knowledge, however, less is known regarding the effe

Metabolic risk factors in prostate cance

Metabolic risk factors in prostate cancer

✍ David I. Chu; Stephen J. Freedland 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

Metabolic syndrome and risk of bladder c

Metabolic syndrome and risk of bladder cancer: prospective cohort study in the metabolic syndrome and cancer project (Me-Can)

✍ Christel Häggström; Tanja Stocks; Kilian Rapp; Tone Bjørge; Björn Lindkvist; Han 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 156 KB 👁 2 views

## Abstract There are little data on the putative association between factors in the metabolic syndrome (MetS) and risk of bladder cancer. In the Metabolic Syndrome and Cancer project (Me‐Can), measurements of height, weight, blood pressure and circulating levels of glucose, cholesterol, and trigly

Citrate transport and metabolism in mamm

Citrate transport and metabolism in mammalian cells : Prostate epithelial cells and prostate cancer

✍ Maria E. Mycielska; Ameet Patel; Nahit Rizaner; Maciej P. Mazurek; Hector Keun; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 348 KB 👁 1 views

The metabolic syndrome and risk of incid

The metabolic syndrome and risk of incident colorectal cancer

✍ Rehana L. Ahmed; Kathryn H. Schmitz; Kristin E. Anderson; Wayne D. Rosamond; Aar 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 2 views

## Abstract ## BACKGROUND The authors tested the hypothesis that the metabolic syndrome (≥3 of the following components: high blood pressure, increased waist circumference, hypertriglyceridemia, low levels of high‐density lipoprotein cholesterol, or diabetes/hyperglycemia) is a risk factor for col